

# John Metcalfe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3486841/publications.pdf>

Version: 2024-02-01

29  
papers

844  
citations

623188

14  
h-index

500791

28  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1426  
citing authors

#	ARTICLE	IF	CITATIONS
1	Leptospirosis-associated Severe Pulmonary Hemorrhagic Syndrome, Salvador, Brazil. <i>Emerging Infectious Diseases</i> , 2008, 14, 505-508.	2.0	212
2	Test Variability of the QuantiFERON-TB Gold In-Tube Assay in Clinical Practice. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 206-211.	2.5	155
3	Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. <i>The Lancet Global Health</i> , 2019, 7, e191-e199.	2.9	53
4	Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment. <i>New England Journal of Medicine</i> , 2019, 380, 2178-2180.	13.9	52
5	Chronic lung disease in HIV-infected children established on antiretroviral therapy. <i>Aids</i> , 2016, 30, 2795-2803.	1.0	49
6	Human Immunodeficiency Virus-Associated Chronic Lung Disease in Children and Adolescents in Zimbabwe: Chest Radiographic and High-Resolution Computed Tomographic Findings. <i>Clinical Infectious Diseases</i> , 2018, 66, 274-281.	2.9	42
7	Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation. <i>The Lancet Global Health</i> , 2019, 7, e798-e807.	2.9	33
8	Evaluation of Quantitative IFN- $\gamma$ Response for Risk Stratification of Active Tuberculosis Suspects. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 87-93.	2.5	32
9	Serial testing for latent tuberculosis using QuantiFERON-TB Gold In-Tube: A Markov model. <i>Scientific Reports</i> , 2016, 6, 30781.	1.6	27
10	Microscopic-Observation Drug-Susceptibility Assay for the Diagnosis of Drug-Resistant Tuberculosis in Harare, Zimbabwe. <i>PLoS ONE</i> , 2013, 8, e55872.	1.1	23
11	Determinants of Multidrug-Resistant Tuberculosis Clusters, California, USA, 2004-2007. <i>Emerging Infectious Diseases</i> , 2010, 16, 1403-1409.	2.0	20
12	Suboptimal specificity of Xpert MTB/RIF among treatment-experienced patients. <i>European Respiratory Journal</i> , 2015, 45, 1504-1506.	3.1	19
13	Tuberculosis outbreak investigation using phylodynamic analysis. <i>Epidemics</i> , 2018, 25, 47-53.	1.5	19
14	Moving Beyond Directly Observed Therapy for Tuberculosis. <i>PLoS Medicine</i> , 2015, 12, e1001877.	3.9	17
15	Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis. <i>PLoS ONE</i> , 2016, 11, e0155887.	1.1	15
16	An LC-MS/MS-based method to analyze the anti-tuberculosis drug bedaquiline in hair. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 1069-1070.	0.6	9
17	Simultaneous analysis of 11 medications for drug resistant TB in small hair samples to quantify adherence and exposure using a validated LC-MS/MS panel. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1125, 121729.	1.2	9
18	Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB. <i>ERJ Open Research</i> , 2019, 5, 00046-2019.	1.1	9

#	ARTICLE	IF	CITATIONS
19	A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1865-1873.	1.3	9
20	Health care seeking patterns of rifampicin-resistant tuberculosis patients in Harare, Zimbabwe: A prospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0254204.	1.1	7
21	A multi-analyte panel for non-invasive pharmacokinetic monitoring of second-line anti-tuberculosis drugs. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 991-992.	0.6	6
22	Presentation and outcome of suspected sepsis in a high-HIV burden, high antiretroviral coverage setting. <i>International Journal of Infectious Diseases</i> , 2020, 96, 276-283.	1.5	6
23	Short Communication: Higher Tenofovir Concentrations in Hair Are Associated with Decreases in Viral Load and Not Self-Reported Adherence in HIV-Infected Adolescents with Second-Line Virological Treatment Failure. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 748-750.	0.5	5
24	Frequent Suboptimal Thermocycler Ramp Rate Usage Negatively Impacts GenoType MTBDRsl VER 2.0 Performance for Second-Line Drug-Resistant Tuberculosis Diagnosis. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 494-502.	1.2	4
25	Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying delamanid and its metabolite in small hair samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1169, 122467.	1.2	3
26	Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting. <i>BMC Infectious Diseases</i> , 2021, 21, 99.	1.3	3
27	Correlation of Linezolid Hair Concentrations with Plasma Exposure in Patients with Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	2
28	Brief Report: Ritonavir Concentrations in Hair Predict Virologic Outcomes in HIV-Infected Adolescents With Virologic Failure on Atazanavir-Based or Ritonavir-Based Second-Line Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 181-185.	0.9	2
29	Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	2